Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
- Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
- Journal: BMC Cancer, 2023
- Citations: 20

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
- Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
- Journal: Future Oncology, 2023
- Citations: 13

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
- Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
- Journal: The Breast, 2022
- Citations: 13

The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
- Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
- Journal: The Breast, 2023
- Citations: 12

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
- Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
- Journal: Journal of Chemotherapy, 2024
- Citations: 4

The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
- Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
- Journal: Future Oncology, 2023
- Citations: 4

Antibody-Drug Conjugates in Triple Negative Breast Cancer
- Authors: M. Keskinkilic, R. Sacks
- Journal: Clinical Breast Cancer, 2024
- Citations: 3

194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
- Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
- Journal: Annals of Oncology, 2022
- Citations: 3

The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
- Authors: H. I. Ellez, M. Keskinkilic, et al.
- Journal: Journal of Clinical Medicine, 2023
- Citations: 11

The role of immune checkpoint inhibition in triple-negative breast cancer
- Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
- Journal: Expert Review of Anticancer Therapy, 2023
- Citations: 10

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
- Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
- Journal: Journal of Cancer Research and Clinical Oncology, 2023
- Citations: 5

CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
- Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
- Journal: The Prostate, 2022
- Citations: 5

A severe case of levothyroxine intoxication successfully treated in intensive care unit
- Authors: Y. Savran, T. Mengi, M. Keskinkilic
- Journal: Journal of Acute Disease, 2018
- Citations: 11

Ms. ‌Teng Zhang |Gynecologic Oncology |Young Scientist Award

Ms at Qilu Hospital of Shandong University, China

Ms. Teng Zhang is an accomplished Attending Doctor in the Department of Obstetrics and Gynecology at Qilu Hospital of Shandong University. With a Ph.D. and Master’s degree from Cheeloo College of Medicine, Shandong University, and a Bachelor’s degree from Jining Medical College, Ms. Zhang has extensive experience in clinical practice and research. Notable achievements include publications on cervical cancer in high-impact journals and awards in English teaching competitions. Dr. Zhang’s research focuses on fertility-sparing treatments, m6A methylation, and immune cell variations in cervical cancer, underscoring a strong commitment to advancing women’s health.

Profile

Scopus

🎓 Education Background

Sept. 2015 – Sep. 2018: Ph.D., Cheeloo College of Medicine, Shandong University. Sept. 2013 – Sep. 2015: Master, Cheeloo College of Medicine, Shandong University. Sept. 2008 – Jun. 2013: Bachelor of Medicine, Jining Medical College. Sept. 2005 – Jun. 2008: Qingdao No.2 Middle School

💼 Research/Work Experience

July 2022 – Present: Attending Doctor, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University. Nov. 2018 – June 2021: Resident, Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University. June 2016 – June 2017: Visiting Scholar, Griffith University, Australia

🏆 Scholarships and Awards

2023: Young Teachers English Teaching Competition, Second Prize, Cheeloo College of Medicine, Shandong University, 2021: The First “Guangzhi Cup” English Teaching Competition in Qilu Hospital of Shandong University, Third Prize, July 2013: Excellent Graduate of Shandong Province, Oct. 2009: National Scholarship

Publications Top Notes 📝

Xuji Jiang, Chuanli Feng, Wanying Sun, Teng Zhang*, Baoxia Cui. “The top 100 most cited articles on fertility-sparing treatments for cervical cancer: A bibliometric analysis.” Heliyon, 10(11), 2024.

Zhonghao Mao, Bingyu Wang, Teng Zhang, Baoxia Cui*. “The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.” Cell Death and Disease, 2023, 14(734).

Teng Zhang, Jun Jiao, Xinlin Jiao, Lu Zhao, Xinli Tian, Qing Zhang, Daoxin Ma, Baoxia Cui*. “Aberrant frequency of TNFR2+ Treg and related cytokines in patients with CIN and cervical cancer.” Oncotarget, 2017, 9(4).

Bingyu Wang, Zhonghao Mao, Jinwen Ye, Xinlin Jiao, Teng Zhang, Qi Wang, Sai Han, Youzhong Zhang, Chunling Wang, Taotao Dong, Baoxia Cui. “Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer.” The Journal of Immunology, 2024, 15(212).

Zhang W, Tian X, Mumtahana F, Jiao J, Zhang T, Croce K.D., Cui B*. “The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.” BMC Cancer, 2015, 15,717.

Jun Jiao, Teng Zhang, Xinlin Jiao, Tingting Huang, Lu Zhao, Daoxin Ma, Baoxia Cui*. “hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion.” J Cell Physiol, 2019, 1-9.

Xinlin Jiao, Siying Zhang, Jun Jiao, Teng Zhang, Wenjie Qu, Guy Mutangala Muloye, Beihua Kong, Qing Zhang, Baoxia Cui*. “Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.” Clin Epigenetics, 2019, 11(120).

Merve Keskinkilic | Medical Oncology | Best Researcher Award